Ai Tech
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
TechCrunch·September 23, 2026·1 min read
Enveda, an AI biotech, raised $311 million in a funding round that values the company at $2 billion. The company is developing nature-derived drugs for skin conditions and weight-loss maintenance after GLP-1 treatment, and the new capital will advance these candidates into clinical trials.
Read at TechCrunchDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.